Neuland Laboratories Ltd
Company Profile
Business description
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
Contact
Road No. 82, Jubilee Hills
Plot No. 573A-III, Phoenix IVY Building
11th Floor (5th Office Level)
HyderabadTG500033
INDT: +91 4067611600
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
3,304
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
stocks
Nvidia: Back in business in China; Raising fair value estimate
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,890.80 | 74.40 | 0.84% |
CAC 40 | 7,817.33 | 95.24 | 1.23% |
DAX 40 | 24,267.71 | 258.33 | 1.08% |
Dow JONES (US) | 44,386.34 | 131.56 | 0.30% |
FTSE 100 | 8,970.64 | 44.09 | 0.49% |
HKSE | 24,498.95 | 18.81 | -0.08% |
NASDAQ | 20,755.84 | 25.35 | 0.12% |
Nikkei 225 | 39,901.19 | 237.79 | 0.60% |
NZX 50 Index | 12,905.41 | 150.82 | 1.18% |
S&P 500 | 6,268.56 | 4.86 | 0.08% |
S&P/ASX 200 | 8,639.00 | 77.20 | 0.90% |
SSE Composite Index | 3,516.83 | 13.05 | 0.37% |